Biocon launches cancer medicine in the US

Biopharmaceuticals manufacturer Biocon Ltd launched cancer medication Everolimus tablets in the US. The formulation, a generic version of Afinitor from Novartis, is a prescription medication that is used to treat certain types of cancers and tumours. The tablet has annual sales of around $675 mln in the US, which makes it among the larger drugs […]

Zydus Cadila launches affordable breast cancer drug in India

Zydus Cadila, the pharmaceutical arm of the Zydus group, said it has launched a next-generation breast cancer drug in India at a fraction of its existing cost. The drug, Trastuzumab Emtansine, is considered the first targeted chemotherapy drug for breast cancer as it directs the cytotoxic activity at cancer cells by using a known biomarker. […]

Lupin, Natco get FDA nod to launch generic version of Gleevec cancer drug

Pharmaceutical major Lupin and partner Natco Pharma received approval from the US Food and Drug Administration (FDA) to sell a generic equivalent of Novartis Pharmaceuticals’ Gleevec cancer tablets in the US market. Imatinib Mesylate Tablets, in 100 and 200 mg doses, have annual sales of around $655 million in the United States, Lupin said, making […]

Wockhardt gets nod to launch generic version of Novartis’ Gleevec cancer drug in USA

Indian pharmaceuticals manufacturer Wockhardt said it received approval from the United States Food & Drug Administration to launch a generic version of Novartis’ Leukemia drug Gleevec. The drug is estimated to have sales of $707 million in the US. The Indian company, which already has many of its products on US pharmacy shelves, said it […]

Glenmark Pharma buy rights to cancer drug from US firm

Glenmark Pharmaceuticals said it entered into a licensing agreement with Boston-based biopharmaceutical company APC Therapeutics Inc for exclusive rights for a cancer drug. The agreement covers a small molecule based on Antigen Presenting Cell (APC) biology, the Indian company said. “The compound has the potential to be used as a monotherapy or in combination with […]

Mylan and Biocon submits breast cancer drug application to USFDA

Mylan N.V. and Biocon Ltd. said they submitted Mylan’s biologics license application for a proposed biosimilar Trastuzumab, to the U.S. Food and Drug Administration. Biosimilar trastuzumab is a proposed biosimilar to branded Trastuzumab, which is indicated to treat certain HER2-positive breast and gastric cancers. HER2-positive breast cancer is a breast cancer that tests positive for […]

Glenmark announces discovery of novel cancer drug

Glenmark Pharmaceuticals has announced the discovery of a new anti-cancer therapy by its Swiss subsidiary. The new drug, GBR 1302, will target breast cancer and ovarian cancer, and the company expects to start clinical studies this year. Unlike normal drugs, the new drug will work by making it easier for human body’s defence mechanism, white […]